Sugi Predict

Sugi Predict / Compounds / SCHEMBL21133680

SCHEMBL21133680

SCHEMBL21133680

CCc1cc2c(cc1N1CCC(N3CCNCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 1.00
▸ KDR P35968 4/20 0.86
▸ EML4 Q9HC35 3/20 0.85
▸ SRPK2 P78362 2/20 0.85
▸ SRPK1 Q96SB4 2/20 0.85
▸ GAK O14976 1/20 0.85
▸ ACOX3 O15254 1/20 0.85
▸ NR1I2 O75469 1/20 0.85
▸ ABCB11 O95342 1/20 0.85
▸ EGFR P00533 1/20 0.85
▸ ESR1 P03372 1/20 0.85
▸ PGR P06401 1/20 0.85
▸ RET P07949 1/20 0.85
▸ ROS1 P08922 1/20 0.85
▸ ADORA3 P0DMS8 1/20 0.85
▸ PHKG2 P15735 1/20 0.85
▸ FER P16591 1/20 0.85
▸ EPHA1 P21709 1/20 0.85
▸ DRD1 P21728 1/20 0.85
▸ SLC6A2 P23975 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL897920 0.94 ALK (1.00) ALKKDREML4SRPK2SRPK1
SCHEMBL29962332 0.94 ALK (1.00) ALKKDREML4SRPK2SRPK1
SCHEMBL898091 0.94 ALK (0.97) ALKKDREML4SRPK2SRPK1
SCHEMBL29962590 0.94 ALK (0.97) ALKKDREML4SRPK2SRPK1
SCHEMBL29962653 0.94 ALK (0.95) ALKKDREML4SRPK2SRPK1
SCHEMBL898391 0.94 ALK (0.89) ALKKDREML4SRPK2SRPK1
SCHEMBL29962525 0.94 ALK (0.89) ALKKDREML4SRPK2SRPK1
SCHEMBL1703476 0.94 ALK (0.95) ALKKDREML4SRPK2SRPK1
SCHEMBL897434 0.93 ALK (1.00) ALKKDREML4SRPK2SRPK1
SCHEMBL29961847 0.93 ALK (1.00) ALKKDREML4SRPK2SRPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
EP-3725771-B1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF UNIV SHANGHAI TECHNOLOGY (CN) 2026-02-04 — — EP disclosed
US-20260027217-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-01-29 — — US disclosed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 — — EP disclosed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 — — CN disclosed
US-12233128-B2 Degraders that target ALK and therapeutic uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-02-25 — — US disclosed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 — — WO disclosed
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 — — WO disclosed
EP-3856192-B1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF DANA FARBER CANCER INST INC (US) 2024-09-11 — — EP disclosed
WO-2020249048-A1 ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF 上海科技大学 2020-12-17 — — WO disclosed
CN-112079866-A ALK protein regulator and anti-tumor application thereof 上海科技大学 2020-12-15 — — CN disclosed
EP-3725771-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF Shanghaitech University (CN) 2020-10-21 — — EP disclosed
EP-3725771-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF Shanghaitech University (CN) 2020-10-21 — — EP disclosed
US-20200306273-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2020-10-01 — — US disclosed
US-20200306273-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2020-10-01 — — US disclosed
WO-2020069106-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 — — WO disclosed
WO-2020069106-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 — — WO disclosed
WO-2019196812-A1 PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE 上海科技大学 2019-10-17 — — WO disclosed
WO-2019114770-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF 上海科技大学 2019-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027217-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF ALK, IGF1R, PDGFRB ALK 1/4885KDR 24/4885EML4 1479/4885
US-12233128-B2 Degraders that target ALK and therapeutic uses thereof ALK, BCR, IDE ALK 1/4885KDR 93/4885EML4 3684/4885
US-20200306273-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF ADRM1, VHL, MDM2 ALK 5/4885KDR 81/4885EML4 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.